Key Inclusion Criteria:

          -  Male or female subjects ≥ 18 years of age

          -  Subjects must have a diagnosis of metastatic histologically or cytologically confirmed
             UM. If histologic or cytologic confirmation of the tumor is not available, clinical
             confirmation of a diagnosis of metastatic UM, as per standard practice for UM, by the
             treating investigator can be obtained, and fall into any of the following categories:

               1. Newly diagnosed subject who has not yet received liver-directed or systemic
                  treatment

               2. Subjects ineligible for any available therapy likely to convey clinical benefit

               3. Subjects who have disease progression after treatment with available therapies
                  and/or who is intolerant to those treatments.

          -  Subjects must have measurable disease by RECIST v1.1, defined as at least one lesion
             that can be accurately measured in at least one dimension (longest diameter to be
             recorded) as ≥ 10 mm with calipers and/or CT scan. Measurable lesions cannot have
             undergone any local treatment (including liver-directed radio- or immune- therapies)
             or radiation nor can any local treatment or radiation involving measurable lesions be
             anticipated.

          -  Willingness to provide newly obtained tumor tissue at baseline and on treatment unless
             contraindicated by medical risk in the opinion of the treating physician

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 2. a.) Arm 2
             (Dose Expansion Phase): Subjects enrolling in Arm 2 must have an ECOG PS of ≤ 3.

        Key Exclusion Criteria:

          -  Subjects who have other malignancy which may interfere with the diagnosis and/or
             treatment of metastatic UM.

          -  Subjects who have thrombocytopenia (platelets < 50 × 109/L) or another major bleeding
             disorder/diathesis.

        Note: Subjects with platelets < 50 × 109/L may be permitted to enroll only in Arm 2 of the
        Dose Expansion Phase at the discretion of the Investigator and the Medical Monitor.

          -  Subjects with known central nervous system (CNS) metastases are only permitted under
             the following conditions: Brain metastases must have been stable for at least 2 months
             since completion of most recent CNS-directed intervention. Subject may be on
             corticosteroids so long as the dose is stable or decreasing at the time of study
             entry. Anti-epileptic therapy is allowed so long as medications are not otherwise
             excluded and seizures have been controlled for at least 4 weeks since last
             anti-epileptic medication adjustment. Subjects with active brain metastases and/or
             leptomeningeal disease are excluded.

               1. Dose Escalation Phase: Subjects with known CNS metastases that meet the above
                  conditions are permitted to enroll in dose escalation.

               2. Arm 1 (Dose Expansion Phase): Subjects with known or suspected CNS metastases are
                  excluded from Arm 1.

               3. Arm 2 (Dose Expansion Phase): Subjects with CNS metastases that meet the above
                  conditions are permitted to enroll in Arm 2.

          -  Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infections; subjects with a
             sustained viral response to HCV treatment or immunity to prior HBV infection will be
             permitted. Subject has known positive human immunodeficiency virus (HIV) antibody
             results or acquired immunodeficiency syndrome (AIDS)-related illness; subjects with
             CD4+ T-cell counts greater than or equal to 350 cells/µL will be permitted, as will
             subjects who have not had an AIDS-related illness within the past 12 months

          -  Subjects with an active infection cannot be enrolled until any required antibiotic
             and/or antifungal therapy has been completed and/or infection is determined to be
             controlled

          -  Subjects who have an uncontrolled intercurrent illness.

          -  Known and possible risk for QT prolongation.

          -  Subjects who are receiving treatment with medications that cannot be discontinued
             prior to study entry and that are considered to be any of the following:

               1. known to be strong Cytochrome P450, family 3, subfamily A (CYP3A) inhibitors, are
                  strong CYP3A inducers, or are sensitive CYP3A substrates with narrow therapeutic
                  indices (TIs)

               2. known to have narrow TIs that are sensitive P glycoprotein (P gp) or breast
                  cancer resistance protein (BCRP) substrates and are administered orally, such as
                  digoxin known to be acid-reducing agents (ARAs) such as histamine H2-receptor
                  antagonists (H2 blockers), and proton pump inhibitors (PPIs). Antacids are
                  acceptable when administered in a staggered dosing manner with FHD-286

          -  Subjects who are receiving systemic steroid therapy or any other systemic
             immunosuppressive medication. Local steroid therapies (inhaled or topical steroids)
             are acceptable. Appropriate steroid replacement to manage endocrine toxicities
             resulting from prior systemic anticancer therapy is permitted. See exclusion criterion
             3 for exceptions regarding steroid therapy for subjects with CNS metastases.

          -  Subjects have undergone any prior treatment with a BRG1/BRM inhibitor.